U.S. Markets open in 1 hr 32 mins

Kimberly-Clark Corporation (KMB)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
131.83-1.14 (-0.86%)
At close: 4:02PM EDT
People also watch
Full screen
Previous Close132.97
Bid127.24 x 100
Ask133.50 x 100
Day's Range131.50 - 133.41
52 Week Range111.30 - 138.87
Avg. Volume1,635,701
Market Cap46.79B
PE Ratio (TTM)21.75
EPS (TTM)6.06
Earnings DateJul 25, 2017
Dividend & Yield3.88 (2.92%)
Ex-Dividend Date2017-06-07
1y Target Est133.79
Trade prices are not sourced from all markets
  • Investopedia2 days ago

    Kimberly-Clark Is a Buy on Undervaluation and Growth Prospects: Goldman

    A GS analyst says the market has underestimated the paper-products company's growth profile.

  • PR Newswire3 days ago

    Kimberly-Clark Corporation Names Jeffrey Melucci General Counsel

    DALLAS, June 19, 2017 /PRNewswire/ -- Kimberly-Clark Corporation (KMB) today announced that Jeffrey Melucci has been elected by the company's Board of Directors as senior vice president and general counsel, effective September 1, 2017. Reporting to Chairman and CEO Thomas J. Falk, Melucci will be responsible for all legal and governmental affairs for the company and will serve on the company's Executive Leadership Team. Melucci succeeds Tom Mielke who will retire from the same role after 29 years with the company and 10 years leading the legal function.

  • Barrons.com3 days ago

    Kimberly-Clarke: Why Goldman Sachs Calls It 'Misunderstood'

    In this past weekend's Barron's, my colleague Reshma Kapadia profile Kimberly-Clark (KMB) CEO Thomas Falk and goal of making the maker of Kleenex "a more nimble competitor." Now Goldman Sachs is out with a note calling Kimberly-Clark "misunderstood." Goldman Sachs analyst Jason English and team explain focus in on what they call the "under-appreciated growth story of a misunderstood asset" that is Kimberly-Clarke: We believe the market is under-estimating KMB’s growth profile and under-valuing the stock as a result. Looking beyond, we expect KMB’s Personal Care segment to resume its leadership role as it advances on its long runway of EM-based penetration and frequency gains.